Global Gene Editing Market Size Study, by Offerings, Technique, Technology, Application and Regional Forecasts 2022-2032

Description

The global gene editing market, valued at approximately USD 4.68 billion in 2023, is anticipated to grow with a robust CAGR of 10.2% during the forecast period 2024-2032. This remarkable growth is driven by transformative advancements in gene editing technologies and the widening spectrum of their applications across various sectors, including healthcare and biotechnology.

Gene editing represents a frontier in biotechnology, enabling precise alterations to genetic material. Key technological frameworks such as CRISPR-Cas9, TALENs, and Zinc Finger Nucleases (ZFNs) have revolutionized genetic engineering by making it more efficient, accessible, and versatile. With applications spanning drug discovery, therapeutic development, genome modification, and clinical diagnostics, the market has witnessed substantial adoption among pharmaceutical firms, research institutions, and biotechnology enterprises.

However, significant challenges persist. The scalability of gene editing solutions and the complexities of manufacturing consistent, high-quality tools remain pressing concerns, potentially impeding market growth. Despite these obstacles, the continuous influx of investments and focus on research and development underline the sector's promising future.

The gene editing market is bifurcated into two primary offerings: products and services. Products, including kits, reagents, libraries, and software, commanded the largest market share in 2023. Their essential role in various workflows, such as cell line engineering and drug development, underscores their significance. Services, encompassing gRNA synthesis and vector construction, also hold considerable promise, driven by increasing demand for precise genome editing solutions in drug discovery and therapeutic applications.

Geographically, North America emerged as the dominant regional market in 2023, bolstered by a surge in approvals for advanced therapies and a robust infrastructure supporting genomic research. Europe closely followed as the second-largest market, while the Asia Pacific region is poised for the fastest growth, attributed to heightened investments in R&D, adoption of genomics technologies, and advancements in genomic data analysis.

Key players driving innovation in the global gene editing market include Thermo Fisher Scientific Inc., Merck KGaA, GenScript, Agilent Technologies, Revvity, Lonza, Sangamo Therapeutics, and others. These industry leaders continue to explore novel applications, ensuring a competitive and rapidly evolving market landscape.

Major market players included in this report are:

Thermo Fisher Scientific Inc.
Merck KGaA
GenScript
Agilent Technologies, Inc.
Revvity
Lonza
Tecan Trading AG
Sangamo Therapeutics
Precision BioSciences
Cellectis S.A.
Regeneron Pharmaceuticals Inc.
AMSBIO
Creative Biogene
Synthego
Takara Bio Inc.

The detailed segments and sub-segments of the market are explained below:

By Offerings

Products
- Kits
- Reagents
- Libraries
- Software
Services
- gRNA Synthesis
- Vector Construction

By Technique

Knock-Out
Knock-In

By Technology

CRISPR
Zinc Finger Nucleases (ZFN)
TALEN

By Application

Genome Editing
Drug Discovery and Development
- Blood Disorders
- Cancer
- CNS Disorders
- Others (Ophthalmology, Infections, Dystrophies)

By Region

North America
- U.S.
- Canada
Europe
- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa

Years Considered for the Study:

Historic Year: 2022
Base Year: 2023
Forecast Period: 2024-2032

Key Takeaways:

Market Estimates & Forecasts for 10 years (2022-2032).
Annualized revenues and regional-level analysis for each market segment.
Competitive landscape, including company profiles and SWOT analysis of top players.
Insights into demand-side and supply-side dynamics, along with technological advancements.

Chapter 1. Global Gene Editing Market Executive Summary

1.1. Global Gene Editing Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Offerings
- 1.3.2. By Technology
- 1.3.3. By Application
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Gene Editing Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Gene Editing Market Dynamics

3.1. Market Drivers
- 3.1.1. Advancements in Gene Editing Technologies
- 3.1.2. Expanding Applications in Drug Discovery
- 3.1.3. Growing Adoption in Precision Medicine
3.2. Market Challenges
- 3.2.1. Scalability and Manufacturing Complexities
- 3.2.2. High Costs of Gene Editing Tools
3.3. Market Opportunities
- 3.3.1. Emerging Applications in Therapeutics
- 3.3.2. Rising R&D Investments in Genomics
- 3.3.3. Increasing Adoption in Emerging Markets

Chapter 4. Global Gene Editing Market Industry Analysis

4.1. Porter's Five Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Disruptive Trends in Gene Editing
4.4. Key Investment Opportunities
4.5. Industry Expert Perspectives

Chapter 5. Global Gene Editing Market Size & Forecast by Offerings (2022-2032)

5.1. Products
- 5.1.1. Kits
- 5.1.2. Reagents
- 5.1.3. Libraries
- 5.1.4. Software
5.2. Services
- 5.2.1. gRNA Synthesis
- 5.2.2. Vector Construction

Chapter 6. Global Gene Editing Market Size & Forecast by Technique (2022-2032)

6.1. Knock-Out
6.2. Knock-In

Chapter 7. Global Gene Editing Market Size & Forecast by Technology (2022-2032)

7.1. CRISPR
7.2. Zinc Finger Nucleases (ZFN)
7.3. TALEN

Chapter 8. Global Gene Editing Market Size & Forecast by Application (2022-2032)

8.1. Genome Editing
8.2. Drug Discovery and Development
- 8.2.1. Blood Disorders
- 8.2.2. Cancer
- 8.2.3. CNS Disorders
- 8.2.4. Others (Ophthalmology, Infections, Dystrophies)

Chapter 9. Global Gene Editing Market Size & Forecast by Region (2022-2032)

9.1. North America
- 9.1.1. U.S.
- 9.1.2. Canada
9.2. Europe
- 9.2.1. UK
- 9.2.2. Germany
- 9.2.3. France
- 9.2.4. Spain
- 9.2.5. Italy
- 9.2.6. Rest of Europe
9.3. Asia Pacific
- 9.3.1. China
- 9.3.2. India
- 9.3.3. Japan
- 9.3.4. Australia
- 9.3.5. South Korea
- 9.3.6. Rest of Asia Pacific
9.4. Latin America
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
9.5. Middle East & Africa
- 9.5.1. Saudi Arabia
- 9.5.2. South Africa
- 9.5.3. Rest of Middle East & Africa

Chapter 10. Competitive Intelligence

10.1. Key Company SWOT Analysis
- 10.1.1. Thermo Fisher Scientific Inc.
- 10.1.2. Merck KGaA
- 10.1.3. GenScript
10.2. Top Strategies Adopted by Market Players
10.3. Company Profiles
- 10.3.1. Thermo Fisher Scientific Inc.
- 10.3.2. Merck KGaA
- 10.3.3. GenScript
- 10.3.4. Revvity
- 10.3.5. Lonza
- 10.3.6. Sangamo Therapeutics
- 10.3.7. Tecan Trading AG
- 10.3.8. Precision BioSciences
- 10.3.9. Cellectis S.A.
- 10.3.10. Regeneron Pharmaceuticals Inc.
- 10.3.11. AMSBIO
- 10.3.12. Creative Biogene
- 10.3.13. Synthego
- 10.3.14. Takara Bio Inc.
- 10.3.15. Bio-Techne

Chapter 11. Research Process

11.1. Data Mining
11.2. Analysis
11.3. Market Estimation
11.4. Validation
11.5. Publishing